Quantcast
Last updated on April 16, 2014 at 7:00 EDT

Computer Exercises May Offer New Hope for Alzheimer’s Patients

September 21, 2012

YOKNEAM, Israel, September 21, 2012 /PRNewswire/ –

World Alzheimer’s Day – As the planet turns its attention to World Alzheimer’s Day, an
emerging technology using focused computer brain exercises may offer new hope to
Alzheimer’s patients and their families.

The NeuroAD system works like this: patients solve challenging computer exercises
ranging from identifying colors, shapes, letters and animals to solving memory games.
Simultaneously, the very same regions of the patient’s brain responsible for memory and
learning receive electromagnetic stimulation, which reactivates brain cell activity.

The combined treatment may work more effectively than either would alone. It has
already shown promising interim results in a clinical trial at Harvard University,
following significant statistical and clinical results from studies in Israel. The NeuroAD
system not only stopped patients’ symptoms from deteriorating, in some cases it actually
improved patients’ cognitive performance to a greater extent than what is currently
available with approved medications.

“It is a completely new and different approach, safe, noninvasive, and painless,” said
Professor of Neurology Alvaro Pascual-Leone of Harvard Medical School, who directed the
Harvard trial. “Tests have shown significant improvement of cognitive functions. As a
result, patients’ daily activities such as taking care of themselves, speaking, and even
recognizing their loved ones have improved dramatically.”

“Wherever we go, physicians are eager to hear about this new technology because
nothing else is available to help patients,” said Eyal Baror, CEO of Israel-based
Neuronix, the company behind the NeuroAD system. “NeuroAD is CE certified, which means
centers in Europe and Asia are already using the device to great success. We are also
aiming at FDA approval within the coming years. It may be a real game-changer for the
management of Alzheimer’s disease.”

Developers are hoping that additional trials now set to take place at leading
neuroscience centers in New York, Nevada and Arizona, in addition to continued work in
Boston, will confirm these earlier findings.

        CONTACT:

        Orly Bar
        Neuronix Ltd.
        +972-54-322-1018
        bar@neuronixmedical.com

SOURCE NEURONIX LTD.


Source: PR Newswire